Approval · Notice of Compliance 16727 · 2015
PROLENSA: Notice of Compliance 16727
Issued March 26, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16727
- Date
- March 26, 2015
- Company
- Bausch & Lomb Inc.Rochester, New York, United States
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Nnon-steroidal anti-inflammatory agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PROLENSA | 02439123 | Marketed |
Medicinal ingredients
- BROMFENAC SODIUM SESQUIHYDRATE 0.07 PER